Biomarin Pharmaceutical Inc (BMRN) 120.28 $BMRN
Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results
at The Street - Fri Apr 24, 11:05AM CDT
Catalyst and Jacobus Pharma are racing to secure FDA approval for a drug to treat a rare muscle-wasting disease.
BMRN: 120.28 (-2.67), CPRX: 3.69 (-0.98)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting
GlobeNewswire - Thu Apr 23, 3:51PM CDT
Interim analysis of prospective natural history increases understanding of Duchenne muscular dystrophy
BMRN: 120.28 (-2.67)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Santhera -- A Duchenne Drug With Positive Study Results That Few Know About
at The Street - Thu Apr 23, 9:01AM CDT
Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Active Equities to Watch in the Health Care Sector -- Cytori Therapeutics, Endo Intl., BioMarin Pharma, Novogen, and Receptos
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENDP: 93.27 (-0.81), BMRN: 120.28 (-2.67), CYTX: 0.99 (+0.01), RCPT: 169.88 (-1.26), NVGN: 6.54 (-0.01)
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 3.72 (+0.06), CAPR: 7.25 (-0.75), BMRN: 120.28 (-2.67), RNA: 18.65 (unch), PFE: 35.27 (-0.09), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88), SMMT: 10.30 (-0.20)
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Tue Apr 21, 3:10PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2015, the compensation committee of BioMarin's board of directors approved the grant to 58 newly hired employees of 48,320 restricted share units in the aggregate and stock options to purchase 1,500 shares of common stock in the aggregate.
BMRN: 120.28 (-2.67)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 120.28 (-2.67), PCYC: 256.59 (-0.51), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), HSP: 87.61 (-0.05), CELG: 118.71 (+2.62), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), AZN: 71.79 (-1.34), JAZZ: 189.42 (+0.33), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
GlobeNewswire - Tue Apr 14, 7:00AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 4:30 p.m. ET to discuss first quarter 2015 financial results and provide a general business update.
BMRN: 120.28 (-2.67)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), GILD: 103.69 (-1.52), INCY: 107.34 (-0.51), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), ABBV: 66.07 (+1.82), REGN: 480.09 (+0.01), CELG: 118.71 (+2.62)
Why 1 Wall Street Firm Thinks BioMarin Pharmaceutical Inc. Could Soar
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 10, 7:02AM CDT
What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing drugs to treat rare and ultra-rare diseases, soared 16% in March, according to data from S&P Capital IQ , after receiving positive commentary from...
BMRN: 120.28 (-2.67), DB: 34.26 (+0.11)
After Yesterday's Rally of 1.78% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Apr 08, 4:00PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $120.29 to a high of $124.81. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $123.50 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 120.28 (-2.67)
Endothelial Dysfunction Therapeutics Clinical Trials Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 08, 9:31AM CDT
The report "Endothelial Dysfunction Global Clinical Trials Review, H1, 2015" provides elemental information and data relating to the clinical trials on Endothelial Dysfunction. Endothelial dysfunction is characterized by a disturbed endothelium-dependent vasodilation and decreased bioavailability of nitric oxide. It has been observed in several diseases and has been widely studied as it is often an early disease event in these. Endothelial dysfunction is associated with a number of cardiovascular diseases. The capacity of peripheral vessels to respond adequately to shear stress and to dilate during exercise is one of the main determinants of exercise capacity in patients with chronic heart failure. Complete report with TOC is available at http://www.rnrmarketresearch.com/endothelial-...eport.html .
BMRN: 120.28 (-2.67), GILD: 103.69 (-1.52), PFE: 35.27 (-0.09)
Midcap Growth Funds Power Ahead Amid March Malaise
at Investor's Business Daily - Tue Apr 07, 6:42PM CDT
March left motion-sick investors in mutual funds adrift in a sea of red. U.S. diversified equity funds slipped an average 0.3% last month. They were up 2.5% for the first quarter as a whole. Stock funds were buffeted by several cross-currents: A...
RCL: 72.47 (-0.26), BMRN: 120.28 (-2.67), TJX: 66.29 (-0.04), CCL: 46.38 (+0.09), TGT: 82.70 (+0.77), NCLH: 51.41 (-0.25), WMT: 79.84 (+0.66), HBI: 32.22 (-2.36)
Biotech Stocks Still Feeling Healthy Despite Bubble Talk
at The Street - Mon Apr 06, 4:20PM CDT
Shareholders feeling vertigo following the steep run-up in healthcare and biotech stocks need not reach for the medicine cabinet or the exit, says Marshall Gordon, Research Analyst at ClearBridge Investments.
JNJ: 101.08 (+0.62), BIIB: 401.71 (-28.57), BMRN: 120.28 (-2.67), ONCE: 61.39 (-0.66), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), XLV: 74.39 (-0.24)
Sarepta's Long Road Ahead
Kanak Kanti De - at Seeking Alpha - Mon Apr 06, 3:29PM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Retrophin Hits High On Bullish Initiation Report
at Investor's Business Daily - Thu Apr 02, 11:33AM CDT
Small orphan-disease company Retrophin (RTRX) jumped to a new high near 26 Thursday after Leerink launched coverage of the stock with an outperform rating. Analyst Joseph Schwartz wrote that the company's strategy depends on the pricing power of...
MNK: 122.01 (-2.84), BMRN: 120.28 (-2.67), RTRX: 24.75 (+0.01)
Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 5:36PM CDT
Sarepta's (SRPT) President and CEO, Christopher Garabedian resigns. Company remains on track to file for its Duchenne muscular dystrophy candidate, eteplirsen's approval in the U.S in mid-2015.
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), SNY: 51.75 (-0.01)
Sarepta Therapeutics Inc.'s CEO Exits: Is the Stock Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 01, 8:10AM CDT
In yet another twist to the ongoing saga of Sarepta Therapetics and its experimental Duchenne muscular dystrophy drug eteplirsen, CEO Chris Garabedian exited late Tuesday, seemingly out of the blue. From the information available at this early...
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24)
Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results
at The Street - Fri Apr 24, 11:05AM CDT
Catalyst and Jacobus Pharma are racing to secure FDA approval for a drug to treat a rare muscle-wasting disease.
BMRN: 120.28 (-2.67), CPRX: 3.69 (-0.98)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting
GlobeNewswire - Thu Apr 23, 3:51PM CDT
Interim analysis of prospective natural history increases understanding of Duchenne muscular dystrophy
BMRN: 120.28 (-2.67)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Santhera -- A Duchenne Drug With Positive Study Results That Few Know About
at The Street - Thu Apr 23, 9:01AM CDT
Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Active Equities to Watch in the Health Care Sector -- Cytori Therapeutics, Endo Intl., BioMarin Pharma, Novogen, and Receptos
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENDP: 93.27 (-0.81), BMRN: 120.28 (-2.67), CYTX: 0.99 (+0.01), RCPT: 169.88 (-1.26), NVGN: 6.54 (-0.01)
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 3.72 (+0.06), CAPR: 7.25 (-0.75), BMRN: 120.28 (-2.67), RNA: 18.65 (unch), PFE: 35.27 (-0.09), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88), SMMT: 10.30 (-0.20)
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Tue Apr 21, 3:10PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2015, the compensation committee of BioMarin's board of directors approved the grant to 58 newly hired employees of 48,320 restricted share units in the aggregate and stock options to purchase 1,500 shares of common stock in the aggregate.
BMRN: 120.28 (-2.67)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 120.28 (-2.67), PCYC: 256.59 (-0.51), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), HSP: 87.61 (-0.05), CELG: 118.71 (+2.62), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), AZN: 71.79 (-1.34), JAZZ: 189.42 (+0.33), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
GlobeNewswire - Tue Apr 14, 7:00AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 4:30 p.m. ET to discuss first quarter 2015 financial results and provide a general business update.
BMRN: 120.28 (-2.67)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), GILD: 103.69 (-1.52), INCY: 107.34 (-0.51), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), ABBV: 66.07 (+1.82), REGN: 480.09 (+0.01), CELG: 118.71 (+2.62)
Why 1 Wall Street Firm Thinks BioMarin Pharmaceutical Inc. Could Soar
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 10, 7:02AM CDT
What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing drugs to treat rare and ultra-rare diseases, soared 16% in March, according to data from S&P Capital IQ , after receiving positive commentary from...
BMRN: 120.28 (-2.67), DB: 34.26 (+0.11)
After Yesterday's Rally of 1.78% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Apr 08, 4:00PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $120.29 to a high of $124.81. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $123.50 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 120.28 (-2.67)
Endothelial Dysfunction Therapeutics Clinical Trials Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 08, 9:31AM CDT
The report "Endothelial Dysfunction Global Clinical Trials Review, H1, 2015" provides elemental information and data relating to the clinical trials on Endothelial Dysfunction. Endothelial dysfunction is characterized by a disturbed endothelium-dependent vasodilation and decreased bioavailability of nitric oxide. It has been observed in several diseases and has been widely studied as it is often an early disease event in these. Endothelial dysfunction is associated with a number of cardiovascular diseases. The capacity of peripheral vessels to respond adequately to shear stress and to dilate during exercise is one of the main determinants of exercise capacity in patients with chronic heart failure. Complete report with TOC is available at http://www.rnrmarketresearch.com/endothelial-...eport.html .
BMRN: 120.28 (-2.67), GILD: 103.69 (-1.52), PFE: 35.27 (-0.09)
Midcap Growth Funds Power Ahead Amid March Malaise
at Investor's Business Daily - Tue Apr 07, 6:42PM CDT
March left motion-sick investors in mutual funds adrift in a sea of red. U.S. diversified equity funds slipped an average 0.3% last month. They were up 2.5% for the first quarter as a whole. Stock funds were buffeted by several cross-currents: A...
RCL: 72.47 (-0.26), BMRN: 120.28 (-2.67), TJX: 66.29 (-0.04), CCL: 46.38 (+0.09), TGT: 82.70 (+0.77), NCLH: 51.41 (-0.25), WMT: 79.84 (+0.66), HBI: 32.22 (-2.36)
Biotech Stocks Still Feeling Healthy Despite Bubble Talk
at The Street - Mon Apr 06, 4:20PM CDT
Shareholders feeling vertigo following the steep run-up in healthcare and biotech stocks need not reach for the medicine cabinet or the exit, says Marshall Gordon, Research Analyst at ClearBridge Investments.
JNJ: 101.08 (+0.62), BIIB: 401.71 (-28.57), BMRN: 120.28 (-2.67), ONCE: 61.39 (-0.66), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), XLV: 74.39 (-0.24)
Sarepta's Long Road Ahead
Kanak Kanti De - at Seeking Alpha - Mon Apr 06, 3:29PM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Retrophin Hits High On Bullish Initiation Report
at Investor's Business Daily - Thu Apr 02, 11:33AM CDT
Small orphan-disease company Retrophin (RTRX) jumped to a new high near 26 Thursday after Leerink launched coverage of the stock with an outperform rating. Analyst Joseph Schwartz wrote that the company's strategy depends on the pricing power of...
MNK: 122.01 (-2.84), BMRN: 120.28 (-2.67), RTRX: 24.75 (+0.01)
Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 5:36PM CDT
Sarepta's (SRPT) President and CEO, Christopher Garabedian resigns. Company remains on track to file for its Duchenne muscular dystrophy candidate, eteplirsen's approval in the U.S in mid-2015.
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), SNY: 51.75 (-0.01)
Sarepta Therapeutics Inc.'s CEO Exits: Is the Stock Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 01, 8:10AM CDT
In yet another twist to the ongoing saga of Sarepta Therapetics and its experimental Duchenne muscular dystrophy drug eteplirsen, CEO Chris Garabedian exited late Tuesday, seemingly out of the blue. From the information available at this early...
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24)
